FDA Approves Olaparib for Ovarian Cancer
(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly…
News
Search Results
Endometrial Cancer
…hereditary non-polyposis colon cancer syndrome or HNPCC), Cowden syndrome, or BRCA1 mutations. People with these genetic disorders may consider having yearly testing for endometrial cancer with a pelvic ultrasound and…
The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer
…TILs, as well as BRCA 1 mutation carriers. BRCA 2 carriers were not observed to benefit from them. The study authors concluded, “that the extent of infiltration is prognostic, not…
Rucaparib Receives Breakthrough Therapy Designation from FDA
…of platinum-sensitive ovarian cancer, specifically in patients with tumors that have BRCA mutations and other DNA deficiencies commonly referred to as “BRCA-like.” An FDA-designated “breakthrough therapy” is a drug to…
What is Lynch Syndrome?
Inherited gene mutations, such as BRCA 1 and BRCA 2, can increase the risk of developing ovarian cancer as well as uterine (endometrial) cancer. Some of these mutations, which affect…
Ask the Experts | What Holds Promise in Ovarian Cancer Research?
…targeted treatment pathway at the time of diagnosis. The ability to determine germline and somatic mutations in BRCA and other BRCA-like genes can determine the best use of treatment strategies…
Maintenance olaparib Improves Progression-Free Survival in Phase III Clinical Trial
…BRCA 1 or 2 positive and newly diagnosed with an advanced stage of high grade serous or endometroid ovarian cancer, primary peritoneal, or fallopian tube cancer. Before starting olaparib, patients…
OCRA Awards Prizes in Ovarian Cancer Research
…for patients. Dr. Adams initial project, Development of Combination Therapy with PARP-inhibitors and Immunomodulation for BRCA-1 Epithelial Ovarian Cancer, explored a combination of PARP-inhibitor and immunotherapy to target CTLA-4 antibodies…
OCRF Invited to Participate in Important New National Research Initiative
…recommendations are published as “Recommendation Statements” and have formed the basis for clinical standards in medical practice. The USPSTF has launched a new initiative on Genetic Risk Assessment and BRCA Mutation…
Ovarian Cancer from Beyond the Ovary: Perspectives on Science, Clinical Progress and Advocacy
…doctors encouraging their patients with a BRCA mutation to undergo bilateral salpingectomy as a preventative measure for ovarian cancer. Dr. Miller took it a step further. “Dianne Miller was an…
Ovarian Cancer Research Alliance Names Winners of Two Prizes in Recognition of Notable Research
…Investigators in honor of his work to advance knowledge of BRCA1-mutant ovarian cancer in order to overcome treatment resistance. A panel composed of select members of OCRA’s Scientific Advisory Committee…
The Overview: October 2020
…participation, and brought patient research advocates together with pharmaceutical companies in an industry roundtable to share opportunities and challenges around this issue. Did you know we all have the BRCA gene? Find…